RPRX - CIK 0001802768
The table below shows Royalty Pharma plc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $718.23M | $596.08M | $664.64M | $1.03B | $460.27M | $526.10M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$477.87M | $503.92M | -$86.65M | -$558.53M | $11.16M | -$599.30M |
| Dividends paid | - | - | - | - | - |
Royalty Pharma plc reported operating cash flow of $2.49B for fiscal year 2025. That is down 10.1% from $2.77B in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from $1.62B (FY 2018) to $2.49B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $50.10M | $708.78M | $0.00 | - | - | - |
| Financing cash flow | -$272.67M | -$941.30M | -$212.00M | -$210.37M | -$220.97M | -$226.67M |